Biolase (BIOL) Regains Nasdaq Compliance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Wall St recovers as yields ease; Moderna lifts healthcare stocks
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- FOMC minutes from July 28-29th meeting
BIOLASE REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT
May 16, 2022 6:30 AM EDTFOOTHILL RANCH, Calif., May 16, 2022 /PRNewswire/ -- BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced that it has received notice from the Nasdaq Stock Market LLC (Nasdaq) on May 13, 2022 informing BIOLASE that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the "Rule") for continued listing on The Nasdaq Capital Market. Consequently, BIOLASE is now in compliance with all applicable listing standards and its common stock will continue to be listed on The Nasdaq Capital Market.
... More